CCR5 deficiency increases risk of symptomatic West Nile virus infection by Glass, William G. et al.
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West Nile virus (WNV), a member of the fl  avi-
virus family, is a reemerging pathogen maintained 
primarily between mosquitoes and birds, with 
humans representing one of several incidental 
hosts. First isolated in Uganda in 1937, WNV 
outbreaks have subsequently been reported in 
the Middle East, Africa, Western Asia, Australia, 
and, most recently, in the US, where it has rap-
idly spread westward and into Latin America and 
the Caribbean since arriving in New York City 
in 1999 (1–4).
Clinical manifestations of WNV infection 
can be quite variable. Epidemiologic studies in-
dicate that although  80% of infections remain 
subclinical,  20% progress to a febrile illness (3). 
Of these, >30% of cases in the US progress to 
neuroinvasive disease, including meningitis, en-
cephalitis, and/or fl  accid paralysis. Survivors of 
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severe disease typically require prolonged reha-
bilitation for chronic neurologic sequelae (5). 
To date, no specifi  c treatments or vaccines for 
WNV disease have been approved by the U.S. 
Food and Drug Administration.
In the US, there were 16,577 laboratory-
confi  rmed cases of WNV reported to the Centers 
for Disease Control and Prevention from 2001 to 
2004, of which 648 were fatal (3.9%; references 
6–9). Elderly and immunocompromised individ-
uals have increased susceptibility to WNV (2, 6, 
10, 11), but genetic risk factors and immunologic 
control mechanisms have not been fully delin-
eated. We have recently identifi  ed the monocyte 
and T lymphocyte chemokine receptor CCR5 as 
a key factor in viral clearance and survival in a 
mouse model of WNV encephalitis, in which the 
mechanism involved traffi   cking  of  leukocytes 
into the infected brain (12). Consistent with this, 
WNV induces expression of CCR5 ligands in 
WNV-infected mouse brain (12, 13).
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West Nile virus (WNV) is a reemerging pathogen that causes fatal encephalitis in several 
species, including mouse and human. Recently, we showed that the chemokine receptor 
CCR5 is critical for survival of mice infected with WNV, acting at the level of leukocyte 
traffi  cking to the brain. To test whether this receptor is also protective in man, we deter-
mined the frequency of CCR5𝖫32, a defective CCR5 allele found predominantly in Cauca-
sians, in two independent cohorts of patients, one from Arizona and the other from 
Colorado, who had laboratory-confi  rmed, symptomatic WNV infection. The distribution of 
CCR5𝖫32 in a control population of healthy United States Caucasian random blood donors 
was in Hardy-Weinberg equilibrium and CCR5𝖫32 homozygotes represented 1.0% of the 
total group (n = 1,318). In contrast, CCR5𝖫32 homozygotes represented 4.2% of Cauca-
sians in the Arizona cohort (odds ratios [OR] = 4.4 [95% confi  dence interval [CI], 1.6–
11.8], P = 0.0013) and 8.3% of Caucasians in the Colorado cohort (OR = 9.1 [95% CI, 
3.4–24.8], P < 0.0001). CCR5𝖫32 homozygosity was signifi  cantly associated with fatal 
outcome in the Arizona cohort (OR = 13.2 [95% CI, 1.9–89.9], P = 0.03). We conclude 
that CCR5 mediates resistance to symptomatic WNV infection. Because CCR5 is also the 
major HIV coreceptor, these fi  ndings have important implications for the safety of CCR5-
blocking agents under development for HIV/AIDS.
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In the present study, we attempted to translate this fi  nding 
to man by analyzing the distribution of the defective CCR5 
allele CCR5∆32 in two independent cohorts of symptomatic 
WNV-seropositive individuals from the US. CCR5∆32 con-
tains a 32-bp deletion within the CCR5 coding sequence and 
encodes a truncated protein that fails to traffi   c to the plasma 
membrane (14). CCR5∆32 originated in Northern Europe 
and is found in homozygous form in  1% of Caucasians in 
the US (15, 16). These individuals completely lack CCR5 
function, but appear healthy, suggesting that any important 
homeostatic functions are compensated for by other leuko-
cyte chemoattractant receptors. In addition to regulating 
monocyte and T cell traffi   cking, CCR5 functions pathologi-
cally as a major HIV coreceptor (16). Accordingly, CCR5∆32 
homozygosity is strongly associated with resistance to HIV—
one of the strongest genetic susceptibility factors known in in-
fectious disease (15, 17). Similarly, the hypothesis that CCR5 
plays an important role in WNV pathogenesis in man predicts 
that the distribution of CCR5∆32 among symptomatic pa-
tients may be strongly skewed relative to its distribution in 
the general population. Here, we test this prediction.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Three cohorts of patients, the Colorado WNV-seropositive co-
hort, the Arizona WNV-seropositive cohort, and the Arizona 
WNV-seronegative cohort, were identifi  ed that had symptom-
atic illness in which WNV was considered in the diff  erential di-
agnosis. Inclusion criteria for patients in these cohorts are defi  ned 
in the Materials and methods section and the clinical characteris-
tics are given in Table I. Genotypes were defi  ned for 247 of the 
261 WNV-seropositive Arizona cases (94.6%); for 148 of the 155 
WNV-seropositive Colorado cases (95.5%); for 143 of 152 and 
72 of 74 of the self-  reporting Caucasian subsets of the Arizona 
and Colorado WNV-seropositive cohorts, respectively; for all 
WNV-  seronegative random blood donors (n = 1,318); and for 
145 of 154 WNV-seronegative subjects from Arizona (94.2%).
Table I. Characteristics of study subjects
All racial groups Caucasians only
Characteristics
Arizona
n = 247
Colorado
n = 148
Combined
n = 395
Ariz WNV−
n = 145
Arizona
n = 143
Colorado
n = 72
Combined
n = 72
Mean age (y) 53 ± 19 50 ± 18 52 ± 19 45 ± 20 57 ± 18 50 ± 18 54 ± 18
Male sex (%) 55.6 48.6 52.8 44.3 53.8 41.7 49.8
Caucasian (%)  57.9 48.6 54.4 13.1 100 100 100
Hispanic (%) 10.1 11.5 10.6 2.8 N/A N/A N/A
Asian/Pacifi  c Islander (%)  2.0 0.0 1.3 0.7 N/A N/A N/A
Native American (%) 2.4 0.0 1.5 2.1 N/A N/A N/A
Black (%) 0.0 0.7 0.3 0.7 N/A N/A N/A
Not specifi  ed (%)  27.5 39.2 31.9 80.7 N/A N/A N/A
Fever (%)a 26.7 24.3 25.8 N/A 34.3 22.2 30.2
Meningitis (%)a 25.9 39.9 31.1 N/A 30.8 43.1 34.9
Encephalitis (%)a 24.7 35.8 28.9 N/A 31.5 34.7 32.6
Not specifi  ed (%)a 22.7 0.0 14.2 N/A 3.5 0 2.3
% Mortality (n) 3.2 (8) 7.4 (11) 4.8 (19) N/A 4.9 (7) 1.4 (1) 3.7 (8)
Arizona and Colorado refer to cohorts of patients with symptomatic seropositive WNV infection. Ariz WNV− refers to a second Arizona cohort of symptomatic patients in 
whom WNV was considered as the diagnosis but ruled out. Data pooled from the WNV+ Arizona and Colorado cohorts are also shown (Combined).
aPatients were classifi  ed into one of the four indicated disease categories by physician interview.
N/A, not available or applicable.
Table II. Association of the CCR5∆32 allele with symptomatic WNV infection in Arizona and Colorado
  CCR5∆32 Genotype, n (%)
  All racial groups   Self-reporting Caucasians
Cohort +/+ +/∆32 ∆32/∆32 +/++ /∆32 ∆32/∆32
Arizona WNV+ 205 (83.0) 31 (12.6) 11 (4.5) 115 (80.4) 22 (15.4) 6 (4.2)
Colorado WNV+ 111 (75.0) 31 (20.9) 6 (4.1) 49 (68.1) 17 (23.6) 6 (8.3)
Combined WNV+ 316 (80.0) 62 (15.7) 17 (4.3) 164 (76.3) 39 (18.1) 12 (5.6)
Arizona WNV− 125 (86.2) 19 (13.1) 1 (0.7) 16 (84.2) 3 (15.8) 0 (0)
RBD N/A N/A N/A 1102 (83.6) 203 (15.4) 13 (1.0)
All patients from Arizona and Colorado had symptoms for which WNV infection was considered as the underlying cause. WNV+, WNV seropositive; WNV−, WNV 
seronegative; +, wild-type CCR5 allele; ∆32, CCR5∆32 allele; RBD, random blood donors; N/A, not applicable.JEM VOL. 203, January 23, 2006  37
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The genotype distribution observed for the combined 
  Arizona and Colorado WNV-seropositive cohorts deviated 
strongly from Hardy-Weinberg equilibrium (P = 0.013), mainly 
  because of increased frequency of CCR5∆32 homozygotes. 
17 (4.3%) of the 395 informative cases in the combined Arizona 
and Colorado seropositive cohorts unstratifi   ed by race were 
CCR5∆32 homozygotes (Table II). This value greatly exceeds 
the percentage of CCR5∆32 homozygotes reported for the 
general US Caucasian population (0.8–1.1%; reference 18). To 
quantitate the signifi  cance of this genotype–disease association, 
we have used as a reference the group of 1,318 healthy Cauca-
sian random blood donors from the US, in which 1.0% were 
CCR5∆32 homozygotes. Compared with this value, the in-
creased frequency of CCR5∆32 homozygotes in both the 
  Arizona and Colorado WNV-seropositive cohorts was highly 
statistically signifi  cant (Table III). When all genotyped WNV-
seropositive cases unstratifi  ed by race were compared with the 
US random blood donors, the odds ratios (OR) for this genetic 
factor were 4.7 for the Arizona cohort (95% confi  dence interval 
[CI], 2.1–10.6, P < 0.0001) and 4.2 for the Colorado cohort 
(95% CI, 1.6–11.3, P = 0.0018). It is important to note that this 
is a conservative analysis   because the frequency of CCR5∆32 
homozygotes is certain to be lower in non-Caucasian racial 
groups from these   cohorts (Table I).
Consistent with this, when the data were stratifi  ed to in-
clude only self-reporting Caucasians in both the WNV-sero-
positive cohorts (n = 215), the strength of the association 
increased by 30% (12 CCR5∆32 homozygotes, 5.6%). When 
the self-reporting Caucasian portions of the two WNV-sero-
positive cohorts were compared separately to the random 
blood donor benchmark, the OR was 4.4 in the Arizona co-
hort (95% CI, 1.6–11.8, P = 0.0013), and 9.1 in the Colo-
rado cohort (95% CI, 3.4–24.8, P < 0.0001).
Although unlikely, it is possible that the large increase in 
frequency of CCR5∆32 homozygotes in these cohorts may 
be caused by an atypical geographic distribution of this allele 
in the general population of Arizona and Colorado. To di-
rectly address this possibility, we analyzed the distribution of 
CCR5∆32 in a symptomatic Arizona WNV-seronegative 
cohort (n = 145). Because the CCR5∆32 allele frequency 
in this cohort (7.2%) is only slightly lower than in the Ari-
zona WNV-seropositive cohort (10.7%) and the US Cauca-
sian random blood donors (8.7%), it is likely that this cohort 
contains only a slightly smaller percentage of Caucasians 
than the other two. Thus, given the size of the Arizona 
WNV-seronegative group, there is suffi   cient power at this 
allele frequency to meaningfully analyze the distribution of 
genotypes. Only one CCR5∆32 homozygote was identifi  ed 
in the cohort (0.7%). Moreover, unlike the WNV-seroposi-
tive cohort, the observed CCR5∆32 genotypic frequencies 
in the WNV-seronegative cohort did not deviate from 
Hardy-Weinberg equilibrium (P > 0.99). This strongly sug-
gests that the general population in Arizona does not have an 
anomalous genetic structure with regard to the CCR5 locus, 
with a skewed increase in CCR5∆32 homozygotes that could 
account for the high frequencies we observed in the WNV-
seropositive cohorts. When the CCR5∆32 homozygote ge-
notype frequency was compared between the race-unstratifi  ed 
Arizona WNV-seronegative and -seropositive cohorts, an 
OR of 6.7 was determined (95% CI, 0.86–52.6, P = 0.07).
With regard to the distribution of CCR5 genotypes in 
symptomatic WNV-seropositive cases as a function of clinical 
outcome, no signifi  cant diff  erences were observed compared 
with the distribution in the overall combined group (Table 
IV) or in the Arizona or Colorado WNV-seropositive cohorts 
considered separately (not depicted), with the exception of 
death (Fig. 1). A total of 19 of 395 individuals in the two co-
horts died from WNV neuroinvasive disease (4.8%), which is 
similar to the national average of mortality reported for WNV 
cases from the past three years: 2002 (4,156 cases, 284 deaths, 
6.8%); 2003 (9,862 cases, 264 deaths, 2.7%); and 2004 (2,539 
Table III. CCR5∆32 homozygotes have increased risk of symptomatic WNV infection
  All racial groups   Self-reporting Caucasians
Cohort OR 95% CI P OR 95% CI P
Arizona 4.7 2.1–10.6 <0.0001 4.4 1.6–11.8 0.0013
Colorado 4.2 1.6–11.3 0.0018 9.1 3.4–24.8 <0.0001
Combined 4.5 2.2–9.4 <0.0001 5.9 2.7–13.2 <0.0001
Values were calculated in comparison to the CCR5∆32 homozygous genotype frequency in 1,318 North American Caucasian random blood donors.
Figure 1.  CCR5 defi  ciency is associated with increased risk of 
death from WNV infection. Data presented are from the Arizona WNV-
seropositive cohort and demonstrate that CCR5∆32 homozygosity is 
associated with fatal outcome in both the race-unstratifi  ed (OR = 8.5 
[95% CI, 1.5–48.2], P = 0.04) and self-reporting Caucasian (OR = 13.2 
[95% CI, 1.9–89.9], P = 0.03) groups.38   CCR5 AND WEST NILE VIRUS PATHOGENESIS | Glass et al.
cases, 100 deaths, 3.9%). The combined total for this time in-
terval in the US is 16,577 reported cases with 648 deaths 
(3.9%; references 7–9). The Arizona WNV-seropositive co-
hort accounted for 8 of the 19 total deaths, 7 in Caucasians 
and 1 in a Hispanic (Table I). The Colorado WNV-seroposi-
tive cohort accounted for 11 deaths, 1 in a Caucasian. Two of 
the 19 fatalities (10.5%) in the combined cohorts were 
CCR5∆32 homozygotes, both self-reporting Caucasians from 
the Arizona WNV-seropositive cohort. The ages of the two 
CCR5∆32 homozygotes who died were 70 and 74, similar to 
the average age of the other 17 fatal cases (74 yr). The two 
CCR5∆32 homozygote fatalities represent 25 and 29% of 
the race-unstratifi  ed (n = 8) and Caucasian (n = 7) Arizona 
WNV-seropositive cases who died, respectively. These values 
exceed the expected values based on the frequency of 
CCR5∆32 homozygotes among the race unstratifi  ed  and 
Caucasian groups in the Arizona cohort (4.5 and 4.2%, re-
spectively), and the diff  erences are statistically signifi  cant: 
OR = 8.5 (95% CI, 1.5–48.2), P = 0.04, and OR = 13.2 
(95% CI, 1.9–89.9), P = 0.03, respectively (Fig. 1). This asso-
ciation was not observed in the Colorado cohort. When Cau-
casians from both cohorts were analyzed together, the association 
test gave an OR of 6.6 (95% CI, 1.2–37), P = 0.07.
The present study provides the fi  rst evidence that the de-
fective CCR5 allele CCR5∆32 is a risk factor for symptom-
atic WNV infection, the fi  rst genetic risk factor identifi  ed 
for this disease. The association was restricted to CCR5∆32 
homozygotes and was very strong, similar in magnitude to 
the association we and others have previously reported for 
CCR5∆32 homozygosity with the exposed, uninfected HIV 
resistance phenotype (e.g., OR = 6.04 [95% CI, 1.42–25.7], 
P = 0.02, in reference 15). Although our results are based 
on retrospective analysis, they are unlikely to be because of 
chance for six reasons. First, the results are statistically strong 
(an OR greater than four). Second, the results were obtained 
in two independent as well as geographically and tempo-
rally   distinct cohorts. Third, CCR5∆32 is a complete loss-
of-function mutation and therefore homozygous individuals 
completely lack functional CCR5. Fourth, WNV infection 
is associated with infi  ltration of T cells and macrophages 
(cell types known to express CCR5) into brains of patients 
infected with WNV, suggesting biologically plausible in-
volvement of CCR5 in regulating leukocyte migration to the 
brains of infected patients (19, 20). Fifth, WNV infection of 
mice induces expression of the CCR5 ligand CCL5 and ac-
cumulation of CCR5+ leukocytes in the brain (12, 13). Sixth, 
WNV infection in CCR5−/− mice is uniformly fatal (12).
Together these results imply that wild-type CCR5 func-
tions as a host defense factor in WNV infection in man. 
CCR5 could potentially restrict WNV infection at the level 
of initial infection. This is not addressed by our retrospective 
study design and may not be feasible to resolve prospectively 
by measuring the association of CCR5∆32 homozygosity 
with asymptomatic WNV infection because this genotype 
and WNV infection are both uncommon in the general pop-
ulation. More likely, CCR5 restricts disease progression after 
initial infection so that its absence results in an increased like-
lihood of an infected patient coming to medical attention as 
a symptomatic case. Our data are consistent with this inter-
pretation, and even suggest that a fatal outcome is more likely 
in the absence of CCR5 (Fig. 1). Additional work will be 
needed to more critically address the latter point because 
the positive association we observed between CCR5 de-
fi  ciency and death in the Arizona cohort, although statisti-
cally signifi  cant, was based on only two cases, and could not 
be detected in the Colorado cohort, possibly because of its 
smaller size.
Another limitation of our study was the incomplete infor-
mation about the racial background of cases (Table I), which 
is needed to more precisely quantitate risk because CCR5∆32 
is primarily found in Caucasians. We have addressed this by 
consistently applying a conservative analysis of the data that 
has enabled us to test boundary conditions for quantitating 
the strength of the genotype–disease association. Larger pro-
spective studies will be needed to more precisely quantitate 
risk as well as to further defi  ne mechanisms in man.
Our data indicate that immunocompromised patients 
could be particularly susceptible to symptomatic WNV in-
fection if CCR5 function is missing or blocked. Additional 
studies will be needed to address this issue, which should in-
clude close monitoring of AIDS patients treated with antago-
nists now in advanced stages of development targeting the 
HIV coreceptor activity of CCR5. Such agents are intended 
to imitate the homozygous CCR5∆32 genetic defect and 
Table IV. Distribution of CCR5∆32 allele as a function of clinical outcome in WNV-seropositive patients
Genotype, n (%)
Clinical outcome
All racial groups   Self-reporting Caucasians
+/+ +/∆32 ∆32/∆32 +/+ +/∆32 ∆32/∆32
Fevera  85 (83.3) 12 (11.8) 5 (4.9) 52 (80.0) 9 (13.8) 4 (6.2)
Meningitisa  100 (81.3) 19 (15.4) 4 (3.3) 59 (78.7) 13 (17.3) 3 (4.0)
Encephalitisa  82 (71.9) 27 (23.7) 5 (4.4) 48 (68.6) 17 (24.3) 5 (7.1)
Not Specifi  eda 49 (87.5) 4 (7.1) 3 (5.4) 5 (100.0) 0 (0) 0 (0)
Death 13 (68.4) 4 (21.1) 2 (10.5) 6 (75.0) 0 (0) 2 (25.0)
Total 316 (80.0) 62 (15.7) 17 (4.3) 164 (76.3) 39 (18.1) 12 (5.6)
Data were pooled from the Arizona and Colorado cohorts.
aPatients were classifi  ed into one of the four indicated disease categories by interview with the referring physician. +, wild-type CCR5 allele; ∆32, CCR5∆32 allele.JEM VOL. 203, January 23, 2006  39
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could render AIDS patients particularly vulnerable to severe 
and possibly fatal WNV infection.
In summary, we have established that homozygous 
CCR5∆32 is a strong host genetic risk factor for symptom-
atic laboratory-confi  rmed WNV infection, the fi  rst one iden-
tifi  ed for this disease. In contrast, the homozygous CCR5∆32 
genotype has previously been strongly associated with re-
sistance to HIV. These genetic data imply that CCR5 plays 
  opposite roles in HIV and WNV infection, facilitating the 
former and restricting the latter. Our results have important 
implications regarding the potential safety of CCR5-block-
ing agents now under development for the treatment of 
HIV/AIDS. Clinical care of individuals taking these medi-
cines while residing in WNV-endemic areas may mandate 
strict measures to limit mosquito exposure and a high index 
of suspicion for symptoms consistent with WNV.
MATERIALS AND METHODS
Study populations. The study was approved by the Offi   ce of Human Sub-
jects Research of the US National Institutes of Health. Four patient groups 
were defi  ned: (a) healthy North American Caucasian random blood donors 
from the National Institutes of Health Department of Transfusion Medicine 
(n = 1,318) previously collected under an IRB approved protocol; (b) the 
Arizona WNV-seropositive cohort (n = 261), defi  ned as patients presenting 
with acute illness in Arizona who tested positive for WNV but negative for 
St. Louis encephalitis virus (SLE) by specifi  c IgM ELISA of serum or cere-
brospinal fl  uid (CSF) at the Arizona Department of Health Services between 
5/26/04 and 10/2/04, the dates for receipt by the Department of the fi  rst 
and last patient samples during mosquito season in the state of Arizona in 
2004; (c) the Colorado WNV-seropositive cohort (n = 155), defi  ned as pa-
tients presenting with acute illness to a physician in Colorado who tested 
positive for WNV but negative for SLE by specifi  c IgM ELISA of serum or 
CSF at the Colorado Department of Public Health and Environment be-
tween 7/20/03 and 9/30/03, the dates for receipt by the Department of the 
fi  rst and last patient samples for 2003; (d) the Arizona WNV-seronegative 
cohort (n = 154), defi  ned as patients presenting with acute illness to a physi-
cian in Arizona in whom WNV and SLE had been considered in the diff  er-
ential diagnosis but ruled out by serological testing at the Arizona Department 
of Health Services between 5/26/04 and 10/2/04. In the Arizona WNV-
seropositive cohort, 89% of the samples collected were available and all of 
these were analyzed. In the Colorado WNV-seropositive cohort, only 164 
samples remained that had a suffi   cient volume for purifi  cation of DNA and 
all of these samples were analyzed. This represented 14% of all Colorado 
samples originally collected. The following information was requested from 
the medical provider during case investigation by local health department 
communicable disease staff  : age, sex, self-reported racial group, and clinical 
presentation based on the Centers for Disease Control–defi  ned clinical pa-
rameters of disease; i.e., fever, meningitis, encephalitis, and death (Table I). 
At the time of data collection each symptomatic patient was classifi  ed into 
one of the three disease categories: fever, meningitis, or encephalitis. Follow-
up data on disease course and the maximal severity of symptomatic disease 
in each patient were not available. All fatal cases were caused by com plications 
of WNV neuroinvasive disease. Study investigators were blinded to unique 
patient identifi  ers.
DNA isolation. 100 μl of serum or CSF was thawed for genomic DNA 
purifi  cation using a QiaAmp 96 DNA Blood kit according to the manufac-
turer’s instructions (QIAGEN). Purifi  ed DNA was eluted into 100 μl of the 
recommended buff  er and stored at 4°C until further use. DNA from random 
blood donors was isolated as previously described (15).
CCR5𝖫32 genotyping. Genotyping was performed by standard methods 
described previously (21). In brief, 2 μl of patient DNA was amplifi  ed by 
PCR using primers that fl  ank the site of the 32-bp deletion: 5′-G  T  C  T  T-
C  A  T  T  A  C  A  C  C  T  G  C  A  G  C  T  C  T  C  -3′ and 5′-G  T  C  C  A  A  C  C  T  G  T  T  A  G  A  G-
C  T  A  C  T  G  C  -3′. PCR products were analyzed by electrophoresis on a 
3.0% agarose/TBE gel with known wild-type CCR5 and CCR5∆32 am-
plicon controls (233 and 201 bp, respectively) and visualized with Gelstar 
(Cambrex) DNA staining. Each sample was tested in two independent 
PCR reactions, and results were concordant, as determined by two inde-
pendent investigators.
Statistical analysis. OR and 95% confi  dence limits were calculated using a 
recessive genetic model (i.e., CCR5∆32 homozygotes compared with the 
combination of wild-type CCR5 and CCR5∆32 heterozygotes) by cross-
tabulation. With the exception of the death data, signifi  cance was deter-
mined by χ2 tests using a two-sided P value and Yates’ continuity correction, 
and 95% CIs were estimated using the approximation of Woolf as imple-
mented in the Prism statistics program version 4 (GraphPad Software). Asso-
ciation of CCR5∆32 homozygosity with death, due to small numbers, was 
analyzed by Fisher’s exact test. Tests of Hardy-Weinberg equilibrium were 
performed using a χ2 test and two degrees of freedom after using the Hardy-
Weinberg equation (p2 + 2pq + q2 = 1, where p and q represent the fre-
quency of the two alleles) to calculate expected frequencies of each of the 
three genotypes.
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